Publications
Stay up to date on CCRAN news and recent advancements in oncology, as CCRAN continues to contribute to the colorectal cancer medical journals and scientific discussions.
Precision medicine is transforming cancer care, but timely and equitable access remain significant barriers. CCRAN is dedicated to overcoming these challenges and ensuring that metastatic cancer patients have access to advanced biomarker testing results. CCRAN's 2024 Biomarker Conference was built on the outcomes of the 2023 inaugural Conference. Over the course of two days, the Conference once again convened clinical, research, policy and patient experts from across multiple cancer types to delve deeper into the access issues in Canada.
Since the 1990s, an increase in the incidence of early-onset cancers has been documented globally. Upward trends in early onset cancer diagnosis are documented across different cancer types, including breast, prostate, thyroid, colon, esophagus, kidney, liver, and pancreas. The most common cancers vary by age group and sex. Lead authors of the publication of early- onset cancer an emerging global epidemic? Current evidence and future implications (Nature Reviews Clinical Oncology, September 2022, 19(10):1-18) will deliver findings from their research and perspectives on the global trends in early-onset cancer from their clinical experience. The symposium will present key findings that highlight the importance of early colorectal cancer screening, particularly in young adults whose symptoms may present differently. Speakers will also elaborate on progress, in terms of new evidence in support of earlier screening, over the past year.A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes
Precision medicines are guided by a tumor's biomarker status and represent a tremendous advancement in cancer treatment. They offer new hope, but systemic barriers to accessing biomarker testing and results need to be addressed. CCRAN's 2023 Conference focused not only on biomarker testing, but also on the utility of CGP and ctDNA testing to improve patient outcomes in Canada.
The symposium will present key findings that highlight the importance of early colorectal cancer screening, particularly in young adults whose symptoms may present differently. Speakers will also elaborate on progress, in terms of new evidence in support of earlier screening, over the past year.A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes
What are the experiences of colorectal cancer patients with biomarker testing in Canada?: a mixed methods study
Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada
Breaking Down Barriers to Detection and Care in Early-Age-Onset Colorectal Cancer in Canada
Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action
A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes
Attitudes of Canadian Colorectal Cancer Care Providers towards Liver Transplantation for Colorectal Liver Metastases: A National Survey